References
 
  1. Cassen B, Curtis L, Reed C, Libby R. Instrumentation for 131I use in medical studies. Nucleonics 1951;9:46-50.

  2. Psarra RA, Papadopoulos SN, Livada D, et al. The single thyroid nodule. Br J Surg 1974;59:545-548.

  3. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-1417.

  4. Joensuu H, Ahonen A, Klemi PJ. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1988;13:502-506.

  5. El-desouki M. Tl 201 thyroid imaging in differentiating benign from malignant thyroid nodules. Clin Nucl Med 1991;16:225-230.

  6. Földes I, Levay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutilisonitrile. Eur J Nucl Med 1993;20:330-333.

  7. Muranake A. Accumulation of radioisotopes with tumor affinity, II. Comparison of the tumor accumulation of Ga-67 citrate and thallium-201 chloride in vitro. Acta Med Okayama 1981;35:85-101.

  8. Sessler MJ, Geek P, Maul FD, et al. New aspects of cellular Tl-201 uptake T+Na+-2Cl-cotransport is the central mechanism of ion uptake. J Nucl Med 1986;25:24-27.

  9. Hoefnagel CA, Delprat CC, Marcuse HR, de Vijlder JJM. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986;27:1854-1857.

  10. Ramanna L, Waxman A, Braunstein G. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 1991;32:441-445.

  11. Iida Y, Hidaka A, Hatabu H, Kasagi H, Konishi J. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 1991;32:2098-2100.

  12. Dadparvar S, Krishna L, Brady Lw, et al. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 1993;71: 3767-3773.

  13. O’Driscoll CM, Baker F, Casey MJ, Duffy GJ. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: a case report. J Nucl Med 1991;32:2281-2283.

  14. Briele B, Hotze AL, Kropp J, Gruenwald F, Rieker O, Biersack HJ. Comparison of 99mTc-MIBI and Tl-201-chloride in the follow-up of patients with differentiated thyroid carcinoma. J Nucl Med 1992;33:844.

  15. Mojiminiyi OA, Udelsman R, Soper ND, Shepstone BJ, Dudley NE. Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid. Clin Nucl Med. 1991; 16:259-262.

  16. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-811.

  17. Diehl M, Risse JH, Brandt-Mainz K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28: 1671-1676.

  18. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001;42:1464-1469.

  19. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42:414-419.

  20. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med 2002;29:641-647.

  21. Van Tol KM, Jager PL, Piers DA, Pruim J, De Vries EG, Dullaart RP, Links TP. Better yield of 18Fluorodeoxyglucose-Positron Emission Tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-387.

  22. Tisell LE, Ahlman H, Wängberg B, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997;84:543-547.

  23. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277-1283.

  24. Postema PTE, De Herder WW, Reubi JC, et al. Somatostatin receptor scintigraphy in nonmedullary thyroid cancer. Digestion 1996; 1(suppl):36-37.

  25. Gulec SA, Serafini AN, Sridhar KS, et al. Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med 1998;39:243-245.

  26. Haslinghuis LM, Krenning EP, de Herder WW, Reijs AEM, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001;24:415-422.

  27. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90YDOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-945.

  28. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptormediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426-434.

  29. Valkema R, Jamar F, Bakker WH, Norenberg J, Smith C, Stolz B, Kvols L, Pauwels S, Krenning EP. Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487;OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. Eur J Nucl Med 2001;28:1025.

  30. Kwekkeboom DJ, Kam BL, Bakker WH, et al. Treatment with 177Lu-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. J Nucl Med 2002;43:34P.

  31. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319-1325.

  32. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997;82:1857-1862.

  33. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996;67:644-647.

  34. Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000;27:1312-1317.

  35. Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Sem Nucl Med 2002;32:97-109.